Stoke Therapeutics Inc [STOK] stock is trading at $15.14, down -0.53%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The STOK shares have gain 10.43% over the last week, with a monthly amount glided 2.92%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Stoke Therapeutics Inc [NASDAQ: STOK] stock has seen the most recent analyst activity on March 26, 2024, when TD Cowen upgraded its rating to a Outperform. On July 25, 2023, downgrade downgraded it’s rating to Market Perform. BofA Securities upgraded its rating to a Neutral and increased its price target to $12 on May 01, 2023. BofA Securities downgraded its rating to Underperform for this stock on January 06, 2023, and downed its price target to $9. In a note dated October 24, 2022, SVB Leerink upgraded an Outperform rating on this stock but restated the target price of $30.
Stoke Therapeutics Inc [STOK] stock has fluctuated between $3.35 and $17.58 over the past year. Currently, Wall Street analysts expect the stock to reach $33.75 within the next 12 months. Stoke Therapeutics Inc [NASDAQ: STOK] shares were valued at $15.14 at the most recent close of the market. An investor can expect a potential return of 122.92% based on the average STOK price forecast.
Analyzing the STOK fundamentals
Stoke Therapeutics Inc [NASDAQ:STOK] reported sales of 15.16M for the trailing twelve months, which represents a growth of 294.72%. Gross Profit Margin for this corporation currently stands at 0.69% with Operating Profit Margin at -7.56%, Pretax Profit Margin comes in at -6.83%, and Net Profit Margin reading is -6.83%. To continue investigating profitability, this company’s Return on Assets is posted at -0.34, Equity is -0.58 and Total Capital is -0.44. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.01.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 14.75 points at the first support level, and at 14.37 for the second support level. However, for the 1st resistance point, the stock is sitting at 15.84, and for the 2nd resistance point, it is at 16.54.
Ratios To Look Out For
For context, Stoke Therapeutics Inc’s Current Ratio is 6.67. In addition, the Quick Ratio stands at 6.67 and the Cash Ratio stands at 4.35. Considering the valuation of this stock, the price to sales ratio is 52.58, the price to book ratio is 3.26.
Transactions by insiders
Recent insider trading involved Blue Horizon E LTD, Affiliate, that happened on Sep 19 ’24 when 1.94 million shares were purchased. CHIEF MEDICAL OFFICER, Ticho Barry completed a deal on Sep 03 ’24 to sell 10000.0 shares. Meanwhile, CHIEF MEDICAL OFFICER Ticho Barry sold 10000.0 shares on Aug 01 ’24.
